Kornimate/medical-research-clean huggingface dataset:
nir-guided sentinel lymph node mapping in melanoma

Conditions: Melanoma

Summary: this study will try to define an appropriate dose of the investigational drug indocyanine green (icg) in combination with near infrared (nir) imaging to use for future studies. icg is a dye which has been in use since the 50s, and is approved for testing liver function and measuring blood flow from the heart. it has been used in studies to map lymphatic pathways in lung and breast cancer and information from those studies suggest it may help identify lymph nodes associated with melanoma. icg can be detected within the body using near-infrared light cameras. in this study the investigators are looking at how easily icg can get to the first lymph node (sentinel lymph node \[sln\]) associated with melanoma, whether the investigators can see the path of the icg and the sln using a near infrared camera, and what dose of icg works the best. while the current method for snl mapping, known as lymphoscintigraphy, is effective it does provide a small amount of radiation. this study will compare the investigators results to the standard procedure.

at the time of surgery, you will undergo a lymphoscintigraphic procedure which is standard of care for patients with melanoma. you will also receive a dose of icg mixed with human serum albumin. this will be administered in four small injections immediately around your tumor or the tumor scar if it has already been removed. pictures of the icg solution will be taken with the nir camera and the progression of the dye along the lymphatic channel from your tumor to the sln will be monitored. as each lymph node is removed, pictures will be taken to see if the icg dye has entered and colored that node. we will compare this technique with the results from the lymphoscintigraphy to measure accuracy. patients will be followed for at least one hour post injection for adverse events. the patient will then be taken off of the study. the results from each intervention will subsequently analyzed.

Eligibility criteria:
inclusion criteria: * histologically confirmed melanoma and an appropriate surgical candidate for a sentinel lymph node biopsy * stage of disease conducive to sentinel lymph node biopsy as determined by oncologic surgeon * receiving a planned lymphoscintigraphy procedure exclusion criteria: * history of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy * pregnant or breast-feeding

Keywords: lymph node
the comparison between the biomarkers in inflammatory bowel disease patients and general control group

Conditions: Inflammatory Bowel Diseases; Irritable Bowel Syndrome

Summary: the aims of this study is to investigate a blood-based biomarker that can replace endoscopy in patients with inflammatory bowel disease. for this purpose, blood sample of patients wiht inflammatory bowel disease (ulcerative colitis, crohn 's disease) was collected at the same time the endoscopy is performed, stored after centrifugation, and analyzed accordingly. selected biomarkers from the blood sample were investigated to compare those of patients with inflammatory bowel disease and those of general controls. males and females over the age of 19 participated in the study and are excluded if they have chronic kidney disease or blood clotting disease. the outcome is a find of a blood-based biomarker that best reflects a disease activity.

inflammatory bowel disease refers to chronic inflammation of the unknown origin that occurs in the intestine. it usually refers to ulcerative colitis and crohn's disease, which are idiopathic inflammatory bowel diseases. while it had been known to be a common disease in the western world, in recent decades the incidence of ulcerative colitis and crohn's disease has rapidly increased in korea as well. endoscopic examination is a gold standard in order to determine the activity of inflammatory bowel disease, but it is hardly performed due to the cost and time of a test. therefore, it is necessary to find a blood-based biomarker that replaces endoscopy. the objective of the study is to identify a new inflammatory marker that replaces endoscopy by comparing blood samples of patients with inflammatory bowel disease with those of general controls.

Eligibility criteria:
inclusion criteria: * people who receive colonoscopy * people who sign the consent * having inflammatory bowel disease (ulcerative colitis, crohn's dz.) and irritable bowel syndrome exclusion criteria: * those aged over 75 years * the disabled * pregnant women * chronic renal diseases (clcr \<50ml/min) * blood coagulopathy (pt inr \> 1.5, aptt \> 45 seconds, or platelet count \< 50,000/mm) * people who refuse to sign the consent

Keywords: reg3 alpha ibd biomarker ulcerative colitis serum calprotectin
oxytocin and fetal heart rate changes

Conditions: Fetal Bradycardia Complicating Labor and Delivery; Fetal Bradycardia During Labor; Fetal Heart Rate or Rhythm Abnormality Affecting Fetus

Summary: the reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. this variability may be due to fluid and oxytocin management prior to and during the initiation of neuraxial analgesia. the study hypothesis is that decreasing the oxytocin infusion rate by 50 % prior to initiation of combined spinal epidural analgesia will cause a reduction in the incidence of adverse fetal heart rate changes.

oxytocin is used in labor and delivery to increase the frequency of contractions and augment uterine contractile strength, thereby establishing a regular pattern of labor. however, the administration of exogenous oxytocin in the presence of an uncoordinated labor pattern confers a risk for an increase in uterine contraction frequency, resulting in inadequate relaxation periods. this leads to an increase in the basal tone of the uterus, which may lead to a tetanic contraction with the risk of decreased uteroplacental blood flow and fetal hypoxemia. previous studies investigating low- versus high-dose oxytocin for induction or augmentation of labor have had conflicting results on the effect on fetal heart rate abnormalities. one of the limitations of these studies is that the labor analgesia was not standardized. the combination of low-dose combined spinal epidural analgesia and the high/low dose oxytocin have not been evaluated. one of the proposed mechanisms for nonreassuring fetal heart a tracing after initiation of analgesia is that the pain relief from neuraxial analgesia causes a decrease in catecholamine release by the sympathetic nervous system. the subsequent decrease in the circulating epinephrine concentration contributes to an increase in uterine tone, as epinephrine is a potent tocolytic agent. the increased tone, in turn, leads to a decrease in placental blood flow, and eventually fetal bradycardia. the primary outcome of this study is the incidence of non-reassuring fetal heart rate tracings within the first 60 minutes after the placement of combined spinal epidural analgesia

Eligibility criteria:
inclusion criteria: * healthy nulliparous or multiparous women at term (37 \> weeks' gestation) * singleton pregnancy * request for neuraxial analgesia * oxytocin used for induction of labor or augmentation of labor per institutional protocols exclusion criteria: * use of chronic analgesic medications * prior administration of systemic opioid labor analgesia * non-vertex presentation * contraindication to neuraxial analgesia * category 3 fetal heart rate tracing prior to the initiation of combined spinal epidural analgesia
beta carotene from natural source for patients with non-active crohn's disease

Conditions: Crohn's Disease

Summary: many inflammatory disorders in the body are linked to oxidative tissue damage. anti-oxidants that are present in many natural food sources may provide protection from such damage. beta carotene is an anti-oxidant vitamin present in many fruits and vegetables. the algae dunaliella is particularly rich in beta carotene. in this prospective trial we want to investigate whether beta carotene from dunaliella may prevent exacerbations of crohn's disease.

patients with documented crohn's disease who are at least 2 months in remission (cdai\<150) will be randomized to receive 60 mg beta carotene/day vs. placebo for 1 year. the study medication will be taken in addition to regular treatment for crohn's disease. the protocol includes 5 visits (months 0, 3, 6, 9, 12). each visit lasts 30-60 minutes and includes a brief interview, standard questionnaires, physical examination, and blood tests. exacerbation of crohn's disease is defined as cdai\>150. the study hypothesis is that less patients treated with beta carotene will suffer an exacerbation than patients treated with placebo.

Eligibility criteria:
inclusion criteria: * patients with documented crohn's disease in remission (cdai\<150) for at least two months, age 17-75 years exclusion criteria: * active crohn's disease (cdai\>150), partial bowel obstruction, impending surgery, pregnancy, serious other diseases

Keywords: crohn's disease remission beta carotene
quantitative assessment of walking (squawk) with the canary canturiotm te (cte) tibial extension

Conditions: Arthritis Knee

Summary: the objective of this prospective study is to demonstrate accuracy of a limp detection model using a healthcare provider assessment as the non-reference standard.

the primary endpoint of the study is limp severity at the 4-6 week office visit. at 4-6 weeks (+/- 3 days) post-surgery, the healthcare team will assess the patient's limp severity by visual observation on a 3-point likert scale (0=no limp, 1=mild/moderate or 2=severe).

Eligibility criteria:
inclusion criteria: * • patient must be 18 years of age or older * independent of study participation, patient is indicated for a commercially available piq tka implant in accordance with product labeling * patient must be willing and able to complete the protocol required follow-up * patient has participated in the study-related informed consent process * patient is willing and able to provide written informed consent by signing and dating the irb approved informed consent exclusion criteria: * • simultaneous bilateral tka * staged bilateral tka less than 6 months from indexed procedure * patient is a current alcohol or drug abuser * patient is known to be pregnant, breastfeeding, or considered a member of a protected class (e.g., prisoner, mentally incompetent, etc.) * patient has a psychiatric illness or cognitive deficit that will not allow proper informed consent and participation in follow-up program * patient with mental or neurologic conditions who are unwilling or incapable of following postoperative care instructions * patient with neuropathic arthropathy * patient with any loss of musculature or neuromuscular disease that compromises the affected limb * patients with known symptomatic foot, hip or spinal injuries and/or conditions that could affect gait

Keywords: total knee arthroplasty personaiq
efficacy and acceptability of thermal ablation in the treatment of cervical neoplasia

Conditions: Cervical Neoplasm

Summary: longitudinal study in two referral centers in morocco to evaluate the effectiveness, the acceptability and safety of thermal ablation in the treatment of cervical neoplasia.

the study population consisted of women with a positive visual inspection with acetic acid (via) screening test referred for ablative treatment. a total of 119 women with lesions eligible to ablative treatment were counselled and treated by thermal ablation. informed consent was signed by each participant. just after treatment, the patients were inquired about the level of pain during the procedure, and their level of satisfaction with the treatment. the women were followed-up at 6 weeks for any complication and re-assessed by colposcopy and biopsy at 12 months for any persistent or recurrent lesion and for any adverse event.

Eligibility criteria:
inclusion criteria: * women having been screened positive at via at the primary health center and referred to the diagnosis centre of fez and taza for ablative treatment by thermal ablation exclusion criteria: * lesion occupying the 4 quadrants of the cervix * not visible squamous columnar junction (not type 1 tz (transformation zone)) * vaginal or endocervical lesion * lesion subjective of cervical cancer
clinical research to explore manifestations of heart failure using infrared thermal imaging technology

Conditions: Heart Failure，Congestive

Summary: the purpose of this study is to explore manifestations of heart failure using infrared thermal imaging technology.

temperature is a vital and useful indicator for various diseases.infrared thermal imaging (irti) allows the temperature representation of the body surface by thermal distribution, where it depends on the complex relationships defining the heat exchange processes between skin tissue, inner tissue, local vasculature, and metabolic activity. the decrease in cardiac output in heart failure activate a series of compensatory adaption that are intended to maintain cardiovascular homeostasis. one of most important adaptation is activation of sympathetic nervous system, which could cause peripheral cutaneous vasoconstriction and decrease the skim temperature. hence, the skim temperature of heart failure would be lower than health people,but which could not discovery by eye. the investigators hypothesize that irti could evaluate heart failure by the imaging of temperature distribution in the face on early stages.the aim of this study is to determine the effectiveness of infrared thermal imaging in evaluating heart failure.

Eligibility criteria:
inclusion criteria: 1. willing to participate in the trial and sign the informed consent form 2. aged: 18-85 years 3. was diagnosed as heart failure 4. there is no trauma, infection, biopsy or puncture, hemorrhage and tumor in the corresponding detection site (face) 5. there is no skin disease, heart, liver, kidney, gastrointestinal tract, hematopoietic system and mental, neurological has no serious diseases exclusion criteria: 1. fever causes by any reasons, temperature higher than 37.4℃ 2. infection 3. renal failure 4. cerebrovascular diseases 5. moderate anemia or more 6. not willing to participate in clinical trials

Keywords: heart failure infrared thermal imaging
a clinical trial to investigate the efficacy of a supplement to improve and maintain cognitive function and memory

Conditions: Cognitive Decline; Cognitive Function

Summary: this study will evaluate the efficacy of 1md nutrition's mindmd supplement in improving and maintaining cognitive function and memory. the randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. participants will be randomized to receive either the test product or a placebo.


Eligibility criteria:
inclusion criteria: * age 50-75 years * regular experience of symptoms related to cognitive decline (e.g., forgetfulness, lack of focus, brain fog) * generally healthy without uncontrolled chronic diseases * willingness to avoid certain medications and supplements during the study exclusion criteria: * any medical condition or treatment impacting cognitive ability mental health or neurological disorders * severe allergies, particularly to soy or other product ingredients * taking blood thinning medication * recent or planned surgeries * major illness in the past three months

Keywords: cognitive health healthy aging
therapeutic role of transcranial dcs in alzheimer

Conditions: Alzheimer Disease

Summary: the aim of this study is to evaluate the oxidative stress and brain damage biomarkers induced by tdcs in patients with ad and to assess the long term neurophysiological and behavioral effects after repeated daily tdcs sessions for 10 days. thirty ad patients diagnosed according to 2011 mckhann criteria will be randomly assigned to receive 10 real anodal tdcs or sham at 2ma intensity for 20 minutes per session daily. all patients will be evaluated at baseline, at the end of the sessions and 1, 2, and 3 months later with neurophysiological and behavioral examination.

the aim of this study is to evaluate the oxidative stress and brain damage biomarkers induced by tdcs in patients with ad and to assess the long term neurophysiological and behavioral effects after repeated daily tdcs sessions for 10 days. thirty ad patients diagnosed according to 2011 mckhann criteria will be randomly assigned to receive 10 real anodal tdcs or sham at 2ma intensity for 20 minutes per session daily. patients were classified into two groups using closed envelope. one group will receive 10 sessions real tdcs and other group will receive sham tdcs. the study will be a double-blind, placebo controlled, within subject, parallel design. tdcs will be delivered bilaterally by a constant current electrical stimulator connected to a pair of sponge electrodes. the investigators will use a non-cephalic reference electrode for tdcs: stimulating electrode will be placed over the left temporo-parietal lobe for 20 minutes and then over the right temporoparietal lobe for another 20 minutes in ad patients, while the reference electrode will be placed over the right deltoid muscle. the stimulating current will be anodal dc at 2 ma intensity delivered for 20 minutes per session for 10 days. all patients will be evaluated at baseline, at the end of the treatment and 1 and 2,and 3months later with neuropsychological and behavioural examination.

Eligibility criteria:
inclusion criteria: * all subject were diagnosed with probable ad according to nincds/adrda criteria for alzheimer's disease. * onset age \> 60. * all 4 grandparents are of ashkenazi jewish origin as declared by the subject. * subject or subject's legal representative has signed the informed consent form. exclusion criteria: * all subjects who were diagnosed with possible ad according to nincds/adrda criteria for alzheimer's disease. * subjects who were diagnosed with dementia due to other diseases, or with ad and contribution of other disorders (mixed dementia): * brain ct/mri suggesting alternative diagnoses, such as intracranial space occupying lesions, vascular lesion of the brain, white matter lesion, or hydrocephalus. * subjects who had known carrier of a blood transmitted infectious disease or suffers from conditions in which phlebotomy is contra-indicated.

Keywords: tdcs, alzheimer disease
prevention of acute kidney injury in cardiac surgery patients

Conditions: Kidney Injury

Summary: acute kidney injury (aki) has no uniform criteria, but is commonly defined as an increase in serum creatinine concentration by at least 25% from baseline. it occurs in 30% of patients following cardiac surgery, and at least 50% of patients with underlying renal insufficiency. patients who have a reduced creatinine clearance pre-operatively are at the greatest risk of developing post-operative aki. the purpose of the current study is to determine if intravenous hydration with either isotonic saline or sodium bicarbonate 150 meq/l is effective at preventing post-operative aki in patients with baseline kidney insufficiency and who are undergoing cardiac surgery using cardiopulmonary bypass. the study hypothesis is that an infusion of sodium bicarbonate 150 meq/l will be more effective than isotonic saline in reducing the incidence of post-operative aki in cardiac surgery patients with a preoperative glomerular filtration rate (gfr) less than 60 ml/min/1.73m2.

this is a randomized, placebo-controlled, prospective, double-blinded. the study will take place at community medical center in scranton, pennsylvania. the inclusion criteria are patients undergoing elective, urgent, or emergent cardiac surgery using cardiopulmonary bypass and having a baseline gfr less than 60 ml/min/1.73m2 estimated using the modification of diet in renal disease equation. patients will be excluded from the study if they have cardiogenic shock (defined as a cardiac index less 2 l/min/m2 despite high dose inotropes or the need for intra-aortic balloon pump), end-stage kidney disease requiring dialysis, received an infusion of sodium bicarbonate on the same day as cardiac surgery, or if they are enrolled in a separate clinical research trial. this trial will involve two treatment groups. group one will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass. group two will receive sodium bicarbonate 150meq in 850ml of a 5% dextrose solution using the same infusion regimen as described above for isotonic saline. the primary efficacy outcome of the study will be the incidence of aki postoperatively. acute kidney injury will be defined as an increase in serum creatinine concentration by at least 25% from baseline or an absolute increase of 0.5 mg/dl at any time within the first five postoperative days.

Eligibility criteria:
inclusion criteria: * elective, urgent, or emergent cardiac surgery using cardiopulmonary bypass * baseline gfr less than 60 ml/min/1.73m2 estimated using the modification of diet in renal disease equation exclusion criteria: * cardiogenic shock (defined as a cardiac index less 2 l/min/m2 despite high dose inotropes or the need for intra-aortic balloon pump) * end-stage kidney disease requiring dialysis * received an infusion of sodium bicarbonate on the same day as cardiac surgery

Keywords: cardiac surgery sodium bicarbonate acute kidney injury saline